Cure8 research brief
The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians spot emerging therapeutic directions and key research sources.
Researchers studying gut–brain or microbiome interactions, clinicians interested in mechanistic links between ENS and IBD, and informed patients following microbiota‑targeted therapies (probiotics, metabolite research).
This paper is a bibliometric analysis (publication and citation patterns) rather than a clinical trial or experimental study.
It summarizes where research activity is concentrated (countries, institutions, journals, and influential authors) and which diseases and mechanisms are most frequently studied, noting that IBD is a prominent clinical focus alongside IBS and neurodegenerative diseases.
The review emphasizes the growing interest in microbiota modulation (for example, probiotics and short‑chain fatty acids) and in neuroinflammatory and neuro‑immune pathways as potential therapeutic targets. It also calls for more international and interdisciplinary collaboration to translate findings into clinical applications.
If you follow IBD research, this article helps identify leading groups, journals, and hot topics to watch but does not provide new clinical evidence or practice-changing results.
This is a bibliometric (publication-pattern) study based on Web of Science and Scopus records, not a report of new experimental or clinical trial data. It synthesizes trends and hotspots but does not evaluate individual study quality or clinical efficacy. Structured content depth: abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...
This method helps translate complex paired microbiome and metabolome data into coherent functional modules; that could clarify microbial metabolic alterations in IBD or IBS and guide future biomarker or mechanistic...
